ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

3:00PM-4:30PM: Abstract Number: 2642

Identifying Systemic Sclerosis Molecular Subtypes by Their Cellular Signature – Deconvoluting the Puzzle

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

3:00PM-4:30PM: Abstract Number: 2653

Impact of Insurance on Time to Biological Drug (bDMARD) Initiation and Inactive Disease Achievement in Patients with Juvenile Idiopathic Arthritis

Abstracts: ARP Interprofessional II: Psychology & Practice

3:00PM-4:30PM: Abstract Number: 2643

Integrated Bulk and Single Cell RNA Sequencing Defines Key Pathways Regulating Myofibroblast Differentiation Across ANA Subgroups in Diffuse Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

3:00PM-4:30PM: Abstract Number: 2624

Measuring Clinically Inactive Disease at One Year in Patients with Juvenile Dermatomyositis (JDM) in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Abstracts: Pediatric Rheumatology – Clinical II

3:00PM-4:30PM: Abstract Number: 2636

Multi-centre Validation of a Serum Protein Biomarker Signature (RAPsA Dx), Which Discriminates Psoriatic Arthritis (PsA) from Rheumatoid Arthritis (RA)

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes II

3:00PM-4:30PM: Abstract Number: 2633

Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification

Abstracts: Sjögren's Syndrome – Basic & Clinical Science

3:00PM-4:30PM: Abstract Number: 2598

p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines

Abstracts: Cytokines & Cell Trafficking

3:00PM-4:30PM: Abstract Number: 2601

Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus

Abstracts: SLE – Etiology & Pathogenesis

3:00PM-4:30PM: Abstract Number: 2618

Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network

Abstracts: Measures & Measurement of Healthcare Quality

3:00PM-4:30PM: Abstract Number: 2615

Prevalence of and Factors Associated with Developing Long COVID Among Patients with Autoimmune Rheumatic Diseases: A Retrospective Cohort Analysis of National U.S. Data

Abstracts: Infection-related Rheumatic Disease

3:00PM-4:30PM: Abstract Number: 2657

Prevalence of Anxiety, Depression, and Fatigue in Patients with Rheumatic Diseases: A Cross-Sectional Study of 1014 Cases

Abstracts: ARP Interprofessional II: Psychology & Practice

3:00PM-4:30PM: Abstract Number: 2622

Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring

Abstracts: Measures & Measurement of Healthcare Quality

3:00PM-4:30PM: Abstract Number: 2646

Rare Variants in the IL1RAP Gene Implicate the IL-1 Signaling Pathway in the Pathogenesis of Systemic Sclerosis in African and European Ancestries

Abstracts: Systemic Sclerosis & Related Disorders – Clinical II

3:00PM-4:30PM: Abstract Number: 2600

Repression of the Aryl-hydrocarbon Receptor Prevents Oxidative Stress and Ferroptosis of Intestinal γδT Cells and Alleviates Systemic Lupus Erythematosus

Abstracts: SLE – Etiology & Pathogenesis

3:00PM-4:30PM: Abstract Number: 2631

Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study

Abstracts: Sjögren's Syndrome – Basic & Clinical Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].